rs892119
|
|
|
0.010 |
GeneticVariation |
BEFREE |
(2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients.
|
22146979 |
2012 |
rs2699887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
(2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients.
|
22146979 |
2012 |
rs7312175
|
|
|
0.010 |
GeneticVariation |
BEFREE |
(3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003).
|
22146979 |
2012 |
rs6443624
|
|
|
0.010 |
GeneticVariation |
BEFREE |
(3) KRAS rs7312175 and PIK3CA rs6443624</span> had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003).
|
22146979 |
2012 |
rs4430796
|
|
|
0.030 |
GeneticVariation |
BEFREE |
rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.
|
25885815 |
2015 |
rs3184504
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A combined analysis revealed one genome-wide significant polymorphism, rs3184504, on chromosome 12q24 (OR = 1.10, P = 7.23 × 10(-9)) with shared effects on CRC and EC risk.
|
26621817 |
2015 |
rs3768235
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A polymorphism in exon 3 (638G-->A) was seen in 4/42 (9.5%) MSI-positive endometrial cancers and 0/5 MSI-positive endometrial cancer cell lines.
|
11180594 |
2001 |
rs1799814
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Accordingly, Thr461Asn status was not significantly associated with endometrial cancer risk.
|
21270613 |
2011 |
rs4775936
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06).
|
22633539 |
2012 |
rs10046
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06).
|
22633539 |
2012 |
rs1256049
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus > or = 22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)].
|
15280642 |
2004 |
rs1271572
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus > or = 22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)].
|
15280642 |
2004 |
rs4680
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Although no obvious associations were detected between COMT Val158Met and endometrial cancer susceptibility in the pooled analysis, we noted significantly decreased endometrial cancer risk for Val/Met versus Val/Val, and Met/Met + Val/Met versus Val/Val genetic models in the postmenopausal female (OR = 0.795, 95%CI = 0.656-0.962, P = 0.019; and OR = 0.819, 95%CI = 0.683-0.983, P = 0.032; respectively), and similar results existed in high-quality studies (OR = 0.835, 95%CI = 0.726-0.961, P = 0.012; and OR = 0.853, 95%CI = 0.747-0.974, P = 0.019; respectively).
|
24390993 |
2013 |
rs1057520001
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An association between endometrial cancer and the polymorphism at codon 31 (AGC/serine to AGA/arginine [Ser(31)Arg]) of the p21 gene, which is known to be a downstream mediator of p53, has also been reported.
|
15099969 |
2004 |
rs886039484
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An association between endometrial cancer and the polymorphism at codon 31 (AGC/serine to AGA/arginine [Ser(31)Arg]) of the p21 gene, which is known to be a downstream mediator of p53, has also been reported.
|
15099969 |
2004 |
rs10012
|
|
|
0.030 |
GeneticVariation |
BEFREE |
An association of CYP1B1 gene R48G polymorphism with endometrial cancer was found [GG vs. GC+CC: odds ratio (OR)=0.55, 95% confidence interval (CI): 0.42-0.73, P<0.0001; GG vs. CC: OR=0.46, 95% CI: 0.23-0.91, P=0.03].
|
21191305 |
2011 |
rs1870050
|
|
|
0.020 |
GeneticVariation |
BEFREE |
An inverse association was found between endometrial cancer and single nucleotide polymorphism rs1870050 in the promoter region with ORs of 0.81 (95% CI, 0.68-0.97) and 0.58 (95% CI, 0.42-0.80) for the AC and CC genotypes, respectively.
|
17507620 |
2007 |
rs12970291
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Another polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, P = 4.82 × 10(-8)), with the alleles showing opposite effects on the risks of the two cancers.
|
26621817 |
2015 |
rs6259
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene.
|
17315164 |
2007 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
rs1131691014
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
rs878854066
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
rs1353702185
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
rs757511141
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects.
|
15723718 |
2005 |